Foundation for the National Institutes of Health

Today marks a pivotal step in the fight against ALS. In partnership with the The National Institutes of Health's National Institute of Neurological Disorders and Stroke (NINDS), FDA, AbbVie, The ALS Association, ALS TDI, ALS United Mid-Atlantic, Answer ALS, The Association for Frontotemporal Degeneration (AFTD), Biogen, Critical Path Institute (C-Path), EMD Serono, Inc., GSK, Eli Lilly and Company, Mitsubishi Tanabe Pharma America, QurAlis, and Target ALS, the FNIH announces the launch of the Accelerating Medicines Partnership® in Amyotrophic Lateral Sclerosis (AMP® ALS), a public-private partnership that promises to bring new hope to patients and their families.     #AMPALS will centralize and build the largest data source for #ALS research, enabling faster breakthroughs and accelerating knowledge sharing among investigators. The program aims to develop reliable biomarkers that could allow for earlier detection of ALS and measures to better track disease progression and evaluate potential treatments.     ALS is a progressive disease that robs people of their ability to move, speak, eat, and ultimately breathe. It is estimated that ALS affects about 30,000 people in the United States, with 4,000 to 6,000 new cases diagnosed each year. With a life expectancy of just 2-5 years after diagnosis, people with ALS don’t have time to wait. AMP ALS aims to expedite the development of therapies that can significantly improves the lives of people with ALS.     With determination and the support of our partners, advocates, champions, and those living with ALS, we can work toward overcoming this devastating disease.     Watch the video and learn more about this effort here: https://lnkd.in/ezPGWJFx #BridgestoBreakthroughs #MND #MotorNeuronDisease #AmyotrophicLateralSclerosis

Development of effective treatments for lupus, which impacts over 1.5 million adults in the United States, have been hampered because the causes of the disease have remained elusive. Now researchers have announced a significant breakthrough in understanding the causes of lupus. Lupus patients often have an imbalanced population of immune cells crucial for controlling inflammation. This imbalance is linked to insufficient activation of aryl hydrocarbon receptor (AHR) related pathways. Boosting AHR could potentially offer a more targeted and effective lupus treatment with fewer side effects. This opens new avenues for combating lupus and other autoimmune diseases and the FNIH-led Accelerating Medicines Partnership® Rheumatoid Arthritis and Systemic Lupus Erythematosus (AMP® RA/SLE) Program is pleased to have played a key role in this research. Read more here https://lnkd.in/dfjUZ57V #Lupus #ARH #autoimmunedisease #AMP #AMPRASLE #FNIH #BridgestoBreakthroughs #rheumatoidarthritis #SLE #SystemicLupusErythematosus

Looking for a career where your work truly makes a difference? Join the FNIH and be part of a dedicated team committed to advancing innovative biomedical research. ✅ Compliance Associate ✅ Director, Biomarkers Consortium ✅ Project Manager Neuroscience ✅ Technical Expert, Regulation and Policy for Genetic Biocontrol Research Explore these exciting opportunities at https://fnih.org/careers #FNIH #Hiring #CareerOpportunities #JoinOurTeam #BridgestoBreakthroughs

This recent review, by authors from the World Health Organization and many collaborators, looked at 511 journal articles assessing the potential impact of climate change on malaria and neglected tropical diseases (NTDs), including vector-borne diseases like arboviruses. One of their conclusions is that the impact of climate change on these diseases isn’t simple: it is “likely to vary by disease and location, be non-linear and evolve over time.” For some diseases they also noted the literature preferentially looked at the potential for increased risk in high-resource settings that currently have a low burden rather than lower-resource settings with fewer resources to respond to higher burdens. Although mitigation and adaptation strategies were infrequently included in the papers they reviewed, the current trajectory of climate change makes it clear that this will be necessary. For vector-borne diseases, genetic biocontrol approaches such as self-sustaining gene drive have the potential to move with vectors as their range and abundance shifts, which could be particularly valuable given the potential unpredictability in the impact of climate change and extreme weather events on vector-borne disease risk. Gene drive approaches for Anopheles and Aedes mosquitoes have been demonstrated in laboratory studies, and some research collaborations are looking ahead to applications for regulatory approval to evaluate their performance in the field. #Malaria #GeneDrive #GeneticBiocontrol Foundation for the National Institutes of Health https://lnkd.in/ewaEBkZf

Great discussion with Reece Armstrong about challenges in treating amyotrophic lateral sclerosis (#ALS) and why a new public-private partnership launched by the Foundation for the National Institutes of Health is hoping to advance new drugs and diagnostics for the disease.  https://lnkd.in/euEbGN8V

How a new partnership aims to tackle ALS DDW Editor Reece Armstrong speaks to Alessio Travaglia, PhD, PMP, Director, Translational Science, Neuroscience, Foundation for the National Institutes of Health (FNIH) about challenges in treating amyotrophic lateral sclerosis (ALS) and why a new public-private partnership launched by the FNIH is hoping to advance new drugs and diagnostics for the disease.  https://lnkd.in/ebHbqXE5 #ALS #Biomarkers #Neuroscience

The FDA has just approved donanemab (Kisunla), a monoclonal antibody developed by Eli Lilly and Company to slow the progression of early symptomatic Alzheimer’s disease. Donanemab helps remove amyloid plaque buildup in the brain, a key factor in Alzheimer’s. Clinical trials have shown significant results, with a 35% lower risk of disease progression over 18 months. While not a cure, donanemab marks the second entry into the first class of disease-modifying drugs for Alzheimer's. This incredible progress is the result of more than 20 years of biomarker research and highlights the importance of public-private collaboration in advancing such medical breakthroughs. The FNIH is committed to continuing its work in developing robust, shareable data sets and sharing knowledge, expertise, and resources to allow researchers to expand their thinking and add new knowledge to solve complex problems like Alzheimer’s and other neurodegenerative diseases. Link here: https://lnkd.in/gcdswNp7 #Alzheimers #AlzheimersResearch #Donanemab #NeurodegenerativeDisease #BiomarkerResearch #AMPAD #BiomarkersConsortium #FNIH

💡 🎙️ Tune in to the latest episode of the Xtalks Life Science Podcast featuring an enlightening conversation with Dr. Alessio Travaglia, PhD, PMP and Dr. Nadia Sethi as they delve into groundbreaking advancements in #ALS research and advocacy. Last month, the Foundation for the National Institutes of Health launched the AMP #ALSresearch program to accelerate the discovery and development of treatments and diagnostics for ALS. This initiative aims to identify biomarkers and clinical outcome assessments for earlier diagnosis and faster drug development. 🎧 Watch + listen to the full episode to learn more about the #FNIH’s AMP ALS program and the crucial role of patient advocacy in ALS research: ➡️ https://buff.ly/4croRWq #DrugDevelopment #Biomarkers #NeurodegenerativeDiseases #AmyotrophicLateralSclerosis #ClinicalOutcomeAssessments #XtalksLifeSciencePodcast #PatientAdvocacy

I'm excited to be speaking at the Fierce Pharma PR & Communications Summit 2024. Please join for our panel on "Next-Level Partnerships" on Monday, July 8 at the Westin in Jersey City, NJ. Learn more https://lnkd.in/e8eXytMy #FiercePharmaPR #FierceBiotech #FiercePharma #WeAreFierce #BiotechEvents #PharmaEvents Fierce Life Sciences Events